Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tetomilast

Drug Profile

Tetomilast

Alternative Names: OPC-6535

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Anti-inflammatories; Anti-ischaemics; Carboxylic acids; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Crohn's disease; Heart failure; Reperfusion injury; Ulcerative colitis

Most Recent Events

  • 09 Sep 2015 Phase-II development is ongoing for Chronic obstructive pulmonary disease in Japan, US and Asia
  • 07 Aug 2015 Otsuka terminates phase II trial in Chronic obstructive pulmonary disorders in USA (NCT00874497)
  • 01 Apr 2014 Otsuka Pharmaceutical completes a phase II in Chronic obstructive pulmonary disease in Japan, China, and South Korea (NCT00917150)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top